Literature DB >> 12468802

Altered vascular function in fetal programming of hypertension.

Delphine Lamireau1, Anne Monique Nuyt, Xin Hou, Sylvie Bernier, Martin Beauchamp, Fernand Gobeil, Isabelle Lahaie, Daya R Varma, Sylvain Chemtob.   

Abstract

BACKGROUND AND
PURPOSE: Reduced endothelium-dependent vasorelaxation partly due to loss of nitric oxide (NO) bioavailability occurs in most cases of chronic hypertension. Intrauterine nutritional deprivation has been associated with increased risk for hypertension and stroke, associated with relaxant dysfunction and decreased vascular compliance, but the underlying mechanisms are not known. The present studies were undertaken to investigate whether endothelial dysfunction associated with altered NO-dependent vasodilatation pathways is also observed in a model of in utero programming of hypertension.
METHODS: Pregnant Wistar rats were fed a normal (18%), low (9%), or very low (6%) protein isocaloric diet during gestation. Vasomotor response of resistance cerebral microvessels (<50 micro m) was studied in adult offspring of dams fed the 18% and 9% protein diets by a video imaging technique. Endothelial NOS (eNOS), soluble guanylate cyclase (sGC), and K(Ca) channel expression were measured by Western blot. NO synthase (NOS) activity was measured enzymatically as well as in situ by NADPH diaphorase staining.
RESULTS: Litter size and survival to adulthood were not affected by the diets. Birth weights of offspring of dams fed the 6% diet were markedly lower than those of dams fed the 9% diet, which were marginally lower than those of controls. Systolic blood pressures of adult offspring of mothers in the 6% and 9% groups were comparably greater (156+/-2 and 155+/-1 mm Hg, respectively) than that of control offspring (137+/-1 mm Hg); we therefore focused on the 9% and 18% groups. Cerebral microvessel constriction to thromboxane A(2) mimetic and dilation to carba-prostaglandin I(2) did not differ between diet groups. In contrast, vasorelaxation to the NO-dependent agents substance P and acetylcholine was diminished by 50% in low protein-exposed offspring, but eNOS expression and activity were similar between the 2 diet groups. Vasorelaxant response to the NO donor sodium nitroprusside was also decreased and was associated with reduced (by 50% to 65%) cGMP levels and sGC expression. cGMP analogues caused comparable vasorelaxation in the 2 groups. Expression of K(Ca) (another important mediator of NO action) and relaxation to the K(Ca) opener NS1619 were unchanged by antenatal diet.
CONCLUSIONS: Maternal protein deprivation, which leads to hypertension in the offspring, is associated with diminished NO-dependent relaxation of major organ (cerebral) microvasculature, which seems to be largely attributed to decreased sGC expression and cGMP levels. The study provides an additional explanation for abnormal vasorelaxation in nutrient-deprived subjects in utero.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12468802     DOI: 10.1161/01.str.0000039340.62995.f2

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  21 in total

Review 1.  Developmental programming of the metabolic syndrome by maternal nutritional imbalance: how strong is the evidence from experimental models in mammals?

Authors:  James A Armitage; Imran Y Khan; Paul D Taylor; Peter W Nathanielsz; Lucilla Poston
Journal:  J Physiol       Date:  2004-09-30       Impact factor: 5.182

2.  Temporal alterations in vascular angiotensin receptors and vasomotor responses in offspring of protein-restricted rat dams.

Authors:  Kunju Sathishkumar; Meena Balakrishnan; Vijayakumar Chinnathambi; Haijun Gao; Chandra Yallampalli
Journal:  Am J Obstet Gynecol       Date:  2012-04-06       Impact factor: 8.661

3.  Newborn lamb coronary artery reactivity is programmed by early gestation dexamethasone before the onset of systemic hypertension.

Authors:  Robert D Roghair; Jeffrey L Segar; Ram V Sharma; Matthew C Zimmerman; D K Jagadeesha; Emily M Segar; Thomas D Scholz; Fred S Lamb
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-06-16       Impact factor: 3.619

4.  Role of fetal programming in the development of hypertension.

Authors:  Norma B Ojeda; Daniela Grigore; Barbara T Alexander
Journal:  Future Cardiol       Date:  2008-03

5.  Maternal alcohol consumption in pregnancy enhances arterial stiffness and alters vasodilator function that varies between vascular beds in fetal sheep.

Authors:  Helena C Parkington; Kelly R Kenna; Foula Sozo; Harold A Coleman; Alan Bocking; James F Brien; Richard Harding; David W Walker; Ruth Morley; Marianne Tare
Journal:  J Physiol       Date:  2014-04-22       Impact factor: 5.182

Review 6.  Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease.

Authors:  Patrick W F Hadoke; Javaid Iqbal; Brian R Walker
Journal:  Br J Pharmacol       Date:  2009-02-23       Impact factor: 8.739

7.  Protein restriction during pregnancy induces hypertension and impairs endothelium-dependent vascular function in adult female offspring.

Authors:  Kunju Sathishkumar; Rebekah Elkins; Uma Yallampalli; Chandra Yallampalli
Journal:  J Vasc Res       Date:  2008-10-29       Impact factor: 1.934

8.  Vascular nitric oxide and superoxide anion contribute to sex-specific programmed cardiovascular physiology in mice.

Authors:  Robert D Roghair; Jeffrey L Segar; Kenneth A Volk; Mark W Chapleau; Lindsay M Dallas; Anna R Sorenson; Thomas D Scholz; Fred S Lamb
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-14       Impact factor: 3.619

9.  Prenatal cocaine exposure differentially causes vascular dysfunction in adult offspring.

Authors:  Daliao Xiao; Xiaohui Huang; Zhice Xu; Shumei Yang; Lubo Zhang
Journal:  Hypertension       Date:  2009-04-20       Impact factor: 10.190

10.  Vulnerability to stroke: implications of perinatal programming of the hypothalamic-pituitary-adrenal axis.

Authors:  Tara K S Craft; A Courtney Devries
Journal:  Front Behav Neurosci       Date:  2009-12-09       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.